Other JAK1/2 inhibitors such as itacitinib (20), abrocitinib (21), solcitinib (22) and filgotinib (23) have shown efficacy in phase II trials in psoriasis and psoriatic arthritis. The gene discussed is JAK1; the disease is psoriasis.